CAPR CLASS ACTION NOTICE: Faruqi & Faruqi, LLP Reminds Capricor Investors of Securities Class Action Lawsuit Deadline on September 28, 2026

Faruqi & Faruqi is investigating potential securities-law claims against Capricor Therapeutics (NASDAQ: CAPR) on behalf of investors who purchased shares between December 17, 2025 and July 26, 2026. Investors have until September 28, 2026 to seek appointment as lead plaintiff in an already filed federal securities class action. The notice creates litigation overhang for Capricor but provides no details on the alleged misconduct or claimed damages.

Analysis

This is a procedural litigation-development signal rather than new evidence of operating deterioration, so the near-term effect is primarily an overhang on CAPR's shareholder base and capital-markets access. In a pre-revenue biotech, the more material transmission mechanism is financing: a weaker share price raises the dilution required for any future equity raise and can reduce negotiating leverage with prospective commercial or strategic partners. The filing itself does not establish liability, damages, or a change in the probability of clinical/regulatory success.

Over the next days to weeks, expect elevated retail-driven volatility and potential price pressure around the lead-plaintiff deadline, but this is usually a poor standalone short catalyst after an initial drawdown. The 1-3 month issue is whether management must revise prior disclosures, faces an SEC inquiry, or signals a cash-runway shortfall; those events would increase both dilution risk and the discount rate investors apply to the pipeline. Conversely, a clean regulatory, clinical, or partnership update can overwhelm litigation noise quickly, making outright bearish positioning vulnerable to sharp squeezes.

The contrarian view is that litigation headlines in small-cap biotech are often economically immaterial relative to binary asset value. CAPR should be valued principally on independently verifiable regulatory milestones, manufacturing readiness, cash runway, and financing terms—not law-firm announcements. There is no read-through to diversified biotech peers or a compelling sector-level trade from this item alone.

Key Decisions for Investors

• Do not initiate a directional CAPR position solely on this notice; treat it as a liquidity and financing-risk flag, not a fundamental catalyst.
• For existing CAPR longs, reduce position size or hedge through the next material company update if cash runway is under 12 months; reassess after any financing announcement, because discounted equity issuance is the principal downside mechanism.
• Avoid naked CAPR shorts into clinical, regulatory, or partnership events over the next 1-3 months; use defined-risk put spreads only if independently confirmed disclosure revisions, an SEC action, or a dilutive financing emerges.
• Set alerts for cash-burn guidance, ATM usage, shelf-registration activity, SEC correspondence, and any change to the relevant regulatory timeline. A runway extension on non-punitive terms or an unambiguous positive regulatory update falsifies the litigation-driven bearish thesis.